Business Wire

CA-NETAPP

4.6.2024 14:01:34 CEST | Business Wire | Press release

Share
Porsche Motorsport Appoints NetApp as Exclusive Intelligent Data Infrastructure Partner

NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced that it has expanded its relationship with Porsche Motorsport to become the exclusive Intelligent Data Infrastructure partner, accelerating access to Porsche Motorsport’s data to drive strategic decision-making on the track. This expansion also creates a new relationship between NetApp and Team Porsche Penske Motorsport in the IMSA WeatherTech SportsCar Championship (IWSC) and World Endurance Championship (WEC), as well as continued support for the TAG Heuer Porsche Formula E Team.

While working with NetApp, the TAG Heuer Porsche Formula E Team has earned four victories in the 2023-2024 Formula E season, putting the team in a competitive position for the season. NetApp’s approach to racing data, via its intelligent data infrastructure, gives the Formula E team real-time access to the data Porsche needs to inform race strategy, support data-driven decision making, and improve outcomes. For example, data-driven simulations help the team pick the best moment to activate the team’s signature Formula E Attack Mode, which unlocks an additional 50 kilowatts of engine power for a well-timed burst of extra speed. With the expanded partnership, Team Porsche Penske Motorsport will leverage NetApp technology in North America to share and analyze the data it needs to drive similar complex decisions in the IWSC and WEC.

“Racing is the ultimate test for technology because speed is literally the name of the game. Only a data infrastructure that’s intelligent can deliver data fast enough to help motorsports teams earn a victory lap,” said Gabie Boko, Chief Marketing Officer at NetApp. “Motorsports generate massive amounts of data during and even before a race that helps them develop their race strategy and respond to changing conditions. The Porsche Motorsport teams need reliable and instantaneous access to their data to stay competitive. As the leader in unified data storage, NetApp is uniquely positioned to help Porsche Motorsport share and analyze its data across its complex and high-performance IT environment wherever and whenever they need it, from the garage to the track.”

With this partnership, Porsche Motorsport can access its data in real time, supporting driver and team performance by leveraging NetApp’s market-leading capabilities, including:

  • Cloud Volumes ONTAP: This offering creates a consistent storage experience for Porsche Motorsport across its hybrid cloud environment, allowing all of the team’s data to be consolidated in the cloud, but accessed anywhere it is needed.
  • BlueXP: Porsche Motorsport uses this software to create a single control plane for managing its data across its hybrid cloud environment, including the capability to create local copies of datasets to conduct low-latency analysis for real-time, trackside decision making.
  • Cloud Backup: Using this capability protects the significant investment of time, money, and expertise Porsche Motorsport has put into creating its data by ensuring high availability and cyber resiliency.

“Motorsports are more about technology than almost anything else. A skilled driver is only as good as the vehicle and race strategy can empower them to be,” said Carlo Wiggers, Director Team Management, Business Relations, and Esports at Porsche Motorsport. “NetApp helps us shine by powering the intelligent data infrastructure that moves our data to the exact place where it will be the most useful. Our teams travel around the world for race events but still need a connection to the data generated by our home base in Germany. NetApp has proven time and again that it can deliver that data reliably and speedily, giving us the confidence to expand our partnership to include the IWSC and WEC events in North America.”

Additional Resource

About NetApp

NetApp is the intelligent data infrastructure company, combining unified data storage, integrated data services, and CloudOps solutions to turn a world of disruption into opportunity for every customer. NetApp creates silo-free infrastructure, harnessing observability and AI to enable the industry’s best data management. As the only enterprise-grade storage service natively embedded in the world’s biggest clouds, our data storage delivers seamless flexibility. In addition, our data services create a data advantage through superior cyber resilience, governance, and application agility. Our CloudOps solutions provide continuous optimization of performance and efficiency through observability and AI. No matter the data type, workload, or environment, with NetApp you can transform your data infrastructure to realize your business possibilities. Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240604479993/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye